Genetic regulation of the growth plate

Elham Karimian*, Andrei S. Chagin and Lars Sävendahl

Pediatric Endocrinology Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden

INTRODUCTION

The bone and cartilage tissues of our skeletal system provide both mechanical support and protection of the vital organs of the body, including the heart, lungs, and brain. Consequently, normal growth and development of skeletal bone is essential. These processes involve two distinct pathways: membranous ossification, which gives rise to calvarial bones directly from osteoblastic cells; and endochondral ossification. The latter, is an important process in the replacement of the fetal skeleton during organogenesis and bone elongation until adult height is achieved.

Bone elongation occurs through proliferation and differentiation of the cells located in the cartilage of the epiphyseal growth plates at the ends of the long bones. These plates are present only during the growth period and vanish when sexual maturation is complete. The growth plate is divided into three well-defined zones. Closest to the epiphysis, the resting zone (also known as the germinal zone) contains single or pairs of small, uniformly round, and relatively quiescent cells embedded in a large volume of extracellular matrix (ECM; Ballock and O’Keefe, 2003; Melrose et al., 2008). Immediately beneath this zone lies the proliferative zone, where the chondrocytes flatten, begin to divide and form ladders parallel to the bone alignment, and synthesize collagen of types II and XI (Ballock and O’Keefe, 2003). In the underlying zone of maturation, referred to as the hypertrophic zone, the chondrocytes which are larger and more swollen than in the other zones, begin their terminal differentiation. The characteristic features of these hypertrophic chondrocytes include a lack of cell division, a pronounced increase in alkaline phosphatase activity and synthesis of large amounts of various elements of the ECM, including type-X collagen, a unique short-chain collagen found only in this zone (O’Keefe et al., 1994; Karimian et al., 2008). This morphological transformation is regulated by various hormones and growth factors, both at systemic and local levels (Figure 1).

LOCAL REGULATION OF THE GROWTH PLATE

The key para/autocrine regulators of bone formation are bone morphogenic proteins (BMPs), fibroblast growth factors (FGFs), hedgehog proteins and parathyroid hormone-related peptide (PTHrP), C-type natriuretic peptide (CNP), vascularization factors and vitamin D, transforming growth factor beta (TGF-β), CCAART/enhancing binding protein beta (C/EBP beta), pannexin 3, cilia and glycosylphosphatidylinositol (GPI).

BONE MORPHOGENIC PROTEINS

Bone morphogenic proteins are growth and differentiation factors which have pivotal roles at every stage of endochondral bone formation and angiogenesis (Mosser and Patterson, 2005; Zhang et al., 2009). Lack of BMPs and/or their receptors results into failure in mesenchymal condensation or digit formation in mice (Storm and Kingsley, 1999; Baur et al., 2000; Pirizette and Niswander, 2000). At later stages, these proteins are expressed in the peri-chondrium as well as hypertrophic and proliferative chondrocytes. Indian hedgehog (Ihh) expression in prehypertrophic chondrocytes increases through BMP signaling (Minina et al., 2001, 2002), thereby increasing both the rate of chondrocyte proliferation and the length of proliferative columns. Furthermore, in vitro these factors directly trigger chondrogenesis by human mesenchymal stem cells to induce the formation of hypertrophic chondrocytes (Steinert et al., 2009).

FIBROBLAST GROWTH FACTORS

Genetic studies have shown that FGF-signaling play a key role in regulating chondrogenesis and 22 different FGFs and four target receptor (FGFR) genes are expressed at every stage of endochondral ossification (Ornitz and Marie, 2002; Ornitz, 2005). FGFs acting via FGF receptor-3 (FGFR3) are the key negative regulators in chondrocyte proliferation. An activation mutation in this receptor inhibits linear bone growth and may cause achondroplasia, hypochondroplasia, or type I or II thanatophoric dysplasia.
At different stages in their development growth plate chondrocytes exhibit different pattern of gene expression. All FGF ligands have the potential to bind FGFR3 as demonstrated in experimental studies. Inhibition of proliferation by FGF-signaling through FGFR3 involves, at least partially, activation of Janus kinase signaling and activator of transcription-1 (JAK–STAT1). The expression of FGFs and their receptors in postnatal growth plate cartilage suggests that these proteins contribute to growth plate senescence and thus help to determine the size of the adult skeleton.

**SIGNALING BY INDIAN HEDGEHOG/PARATHYROID HORMONE-RELATED PROTEIN**

Indian hedgehog, the key paracrine regulator of bone development, orchestrates chondrocyte proliferation, and differentiation, as well as osteoblast differentiation. During bone formation, Ihh is expressed and secreted by post-mitotic hypertrophic chondrocytes simultaneously with expression of the parathyroid hormone-related protein receptor (PPR; Figure 1). Ihh diffuses throughout the growth plate and binds to its receptor, Patched-1 (Ptc-1) expressed by chondrocytes in the resting zone. This, in turn, activates downstream signaling via Smoothened (Smo) and transcription factors of the Gli family and leads to elevation of PTHrP expression. PTHrP is expressed by periarticular chondrocytes, diffuses throughout the growth plate and delays differentiation of columnar chondrocytes into hypertrophic, thereby increasing the distance between the Ihh-expressing domain and the Ihh-targeted cell population. Thereby the Ihh/PTHrP feedback loop is formed which controls fetal growth plate development.

The importance of the Ihh/PTHrP feedback loop for postnatal growth was recently revealed. Inactivation of either Ihh or PPR in postnatal chondrocytes leads to abrupt fusion of the epiphyseal growth plate in mice, suggesting that the loop is crucial for maintaining the growth plate in the open phase.

The importance of the Ihh/PTHrP loop for human physiology is exemplified by the following observations. Both Ihh and PTHrP are expressed in the human growth plate and expression levels correlate with pubertal progression. Inactivating mutation in Ihh results in acrocapitofemoral dysplasia, which is associated with premature closure of the growth plates. Inactivating mutation in the PTH/PTHrP receptor results in Blomstrand dysplasia, which die in uterus, but their skeletal abnormalities closely resembling those of the PTH/PTHrP receptor deficient mice. Furthermore, humans with Jansen chondro-osteodystrophy have point mutations in the gene encoding the PTH/PTHrP receptor that render the receptor active even in the absence of ligand. Such people have growth abnormalities due to
delay in hypertrophic chondrocyte differentiation and resultant short stature. Recently, two reports of families with inactivating, heterozygous mutations of the PTHrP gene show that such heterozygosity for PTHrP causes brachydactyly type E associated with premature cessation of growth in many cases (Kloppoki et al., 2010; Maass et al., 2010). Finally, loss-of-function mutation in the GNAS1 gene, which encodes the α-subunit of the stimulatory G-protein (G<sub>a</sub>), downstream mediator of PPR in chondrocytes (Bastepe et al., 2004), leads to Albright hereditary osteodystrophy (AHO), which often display brachydactyly and premature closure (Bastepe et al., 2004), leads to Albright hereditary osteodystrophy (AHO). Disruption of the genes in mice.

**C-TYPE NATRIURETIC PEPTIDE**

C-type natriuretic peptide is a member of the natriuretic peptide family, together with ANP and BNP proteins (Rosenzweig and Seidman, 1991), and it is widely expressed in many tissues including growth plate cartilages (Hagiwara et al., 1994). It has been identified as a crucial regulator of endochondral bone growth (Chusho et al., 2001; Olney, 2006). CNP promotes chondrogenesis by stimulating expression of molecules involved in cell adhesion and glycosaminoglycan synthesis (Woods et al., 2007). It acts through natriuretic peptide receptor 2 (NPR2). Disruption of the genes encoding CNP or NPR2 results into dwarfism and impaired endochondral ossification (Komatsu et al., 2002; Tamura et al., 2004) in mice.

**VASCULARIZATION FACTORS**

During limb bud development, chondrocytes in the middle of the bud undergo hypertrophic differentiation. Hypertrophic chondrocytes express several chemoattractant proteins, including vascular endothelial growth factor (VEGF; Zelzer et al., 2001), high mobility group box 1 protein (HMG-1; Taniguchi et al., 2007), and receptor activator of NFκB ligand (RANK-L; Kishimoto et al., 2006). This, in turn, attracts blood vessel invasion and brings in endothelial cells, osteoclasts, and osteoblasts leading to formation of the primary ossification center and bone development.

During bone elongation, vascularization is also of extreme importance. Despite the growth plate is an avascular structure, vascularization is important for substitution of cartilage tissue by bone tissue during endochondral ossification. Indeed, inactivating VEGF in mice utilizing soluble VEGF receptor impairs cartilage resorption leading to expansion of the hypertrophic zone and impaired formation of trabecular bone (Gerber et al., 1999). In addition, conditional inactivation of the Vegfa gene in the mouse growth plate leads to delayed invasion of blood vessels into the primary ossification center and delayed removal of terminal hypertrophic chondrocytes together with mass cell death in chondrocytes throughout the growth plate (Zelzer et al., 2004). Interestingly, estrogens can modulate the amount of VEGF expressed by growth plate chondrocytes, thus providing a new plausible mechanism for estrogen-dependent bone formation (Emons et al., 2010). Supporting such a mechanism is the fact that mice overexpressing VEGF in the growth plate dramatically increase their trabecular bone mass whereas the growth plate itself is not affected (Maes et al., 2010). Thus, vascularization is unequivocally important for bone elongation and new bone formation. However, if this process is utilized by the endocrine system to modulate fusion of the growth plate remains to be elucidated.

**VITAMIN D**

Vitamin D needs double hydroxylation, 1α, 25-(OH)2D3, to exert its biological activity (DeLuca, 2004). Vitamin D deficiency results in rickets with disorganized growth plate, impaired mineralization, and widening of the growth plate. 1α, 25-(OH)2D3, locally regulates the growth plate cartilage, partially through a mechanism which involves the nuclear vitamin D receptor (Boyan et al., 2003). Less differentiated chondrocytes, including those in the resting zone, respond to 24,25-(OH)2D3 (Boyan et al., 2002, 2003; Denison et al., 2009) whereas more differentiated cells, including prehypertrophic and hypertrophic chondrocytes, respond primarily to 1α, 25-(OH)2D3 (Boyan et al., 2003). It has been reported that vitamin D receptor knockout mice (VDR<sup>−/−</sup>) arrests longitudinal bone growth 5 weeks after birth and peripheral quantitative computed tomography analysis of the femur midshaft show a significant decrease in all bone parameters (Xue and Fleet, 2009) when compared to the control mice. Disorganized, widened, and expanded growth plates in VDR<sup>−/−</sup> mice indicate the important role of vitamin D on longitudinal bone growth (Xue and Fleet, 2009).

**TRANSFORMING GROWTH FACTOR BETA**

The significance of TGF-β during skeletal development has been well established in different species (Gatherer et al., 1990; Pelton et al., 1990). It has been shown that a mutation in a TGF-β superfamily member causes skeletal dysplasia (Thomas et al., 1996). Recently it has been shown that E-selectin ligand-1 regulates growth plate homeostasis in mice by inhibiting the intracellular processing and secretion of mature TGF-β and therefore prevents skeletal dysplasia (Yang et al., 2010). In addition TGF-β is involved in biomineralization through ankyrin, an important inorganic pyrophosphate transporter (Skubutyte et al., 2010).

**CCAART/ENHANCING BINDING PROTEIN BETA AND PANNEXIN 3**

Transition of the chondrocytes from resting to proliferative and from proliferative to hypertrophic phase is a crucial step for endochondral ossification. The transcription factor (C/EBP beta) promotes the transition of proliferative chondrocytes to hypertrophic chondrocytes through transactivation of p57 (Hirata et al., 2009). Pannexin 3, a member of the gap junction protein family, promotes chondrocytes differentiation from proliferative to hypertrophic by regulating the intracellular ATP/cAMP levels (Iwamoto et al., 2010).

**CILI AND GLYCOSYPHOSPHATIDYLINOSITOL (GPI)**

The primary cilium may be partially responsible for polarization gradients in the growth plate allowing ladder alignment of chondrocytes in the proliferative zone. In addition, primary cilia might be important for transducing Ihh signaling (Koyama et al., 2007). Glycosylphosphatidylinositol (GPI) presumably contributes to this process via cell signaling and adhesion (Ahrens et al., 2009).
SYSTEMIC REGULATION OF THE GROWTH PLATE

During childhood longitudinal bone growth is regulated by a number of key hormones including growth hormone (GH), insulin-like growth factor-I (IGF-I), glucocorticoids, and thyroid hormone. During sexual maturation sex steroids (androgens and estrogens) contribute significantly to this process.

THE GH/IGF-I SYSTEM

From the second trimester of gestation GH is synthesized by the anterior pituitary gland (Kaplan et al., 1972). The physiological role of GH during fetal life is not well understood. During fetal life, IGF-I and IGF-II are generally believed to be the key determinants of embryonic growth (Honnebier and Swaab, 1973; Woods et al., 1996) although a later report indicated that GH may influence fetal development (Waters and Kaye, 2002). On the other hand, following birth and throughout puberty and adulthood GH is well known to play a critical role for longitudinal bone growth (Isaksson et al., 1987; Guler et al., 1988; van der Eerden et al., 2003), exerting anabolic effects on both trabecular and cortical bone (Giustina et al., 2008).

Growth hormone exerts its effects directly by binding to a single-chain trans-membrane glycoprotein receptor (GHR) expressed at high levels in almost all organs including growth plate cartilage (Gevers et al., 2002). At the same time, this hormone stimulates the production of IGF-I (formerly known as somatomedin C) in the liver (Melmed, 1999), which is the major target organ for GH and the principal site of IGF-I production. Also, several extra-hepatic tissues synthesize this hormone under the local control of various hormones including GH (Ohlsson et al., 2009).

Ninety-nine percent of all circulating IGF-I is part of a 150-kD ternary complex also containing its dominant circulatory binding proteins, IGFBP-3 or IGFBP-5, and the acid labile subunit (ALS; Boisclair et al., 2001). This ternary complex stabilizes IGF-I, prolonging its half-life and availability to target organs (Boisclair et al., 2001). Genetic ablation of individual components of this complex (i.e., liver-specific IGF-I, ALS, and IGFBP-3) only partially reduces serum levels of IGF-I and yields only minor skeletal abnormalities, indicating that the remaining serum IGF-I still exerts a substantial impact on the skeleton (Yakar et al., 2009), alternatively, that an elevation in the level of GH is sufficient to compensate for the defect. However, triple-knockout mice lacking liver-specific IGF-I, ALS, and IGFBP-3 exhibit a 97% reduction in their serum level of IGF-I and obvious destruction of bone (Yakar et al., 2009). At the same time, this destruction was markedly less severe than in IGF-I-null mice (Liu et al., 1993), strongly suggesting that local IGF-I and its complexes in tissues, rather than circulating IGF-I, play a major role in skeletal development. Interestingly, a more recent study by Stratikopoulos et al. (2008) showed that mice expressing IGF-I in their livers only attain no more than approximately 30% of the normal adult body size during postnatal development, i.e., that endocrine IGF-I plays a highly significant role in murine growth.

GLUCOCORTICOIDS

Glucocorticoid (GC) therapies often impair growth in both humans and animals (Altman et al., 1992; Allen, 1996; Chrysis et al., 2003), while hereditary deficiencies in these steroids are associated with tall stature (Elias et al., 2000). In rats and humans, epiphyseal cartilage and bone cells express the GC receptor (Silvestrini et al., 1999; Abu et al., 2000) suggesting that GCs exert direct effects on these tissues.

Even low doses of GCs suppress bone growth in both humans and animals, an effect believed to be mediated through disturbance of the GH/IGF-I axis at different levels (Allen, 1996; Smink et al., 2003). Smink et al. (2003) showed that such short-term treatment of mice inhibits growth significantly, decreases the width of the growth plate and the rate of chondrocyte proliferation, promotes apoptosis in hypertrophic chondrocytes, and reduces the local level of IGF-I in the growth plate. Baron et al. (1992) found that local infusion of dexamethasone into the epiphyseal growth plate of one leg of rabbits inhibits the growth of this leg and following dexamethasone withdrawal, catch-up growth in comparison to the contralateral leg occurs. Furthermore, we have recently demonstrated that both dexamethasone-dependent growth inhibition as well as followed catch-up growth occurs in cultured rat metatarsal bones (Chagin et al., 2010). These observations suggest that both the inhibitory effects of GCs on growth, as well as catch-up growth following GC withdrawal are characteristic of the growth plate, even though alterations in the GH/IGF-I system also play a role in this connection.

THYROID HORMONES

Thyroid hormones are important positive regulators of chondrocyte proliferation and hypertrophy (Shao et al., 2006; Mackie et al., 2011). In humans, hypothyroidism leads to retardation of longitudinal bone growth (Rivkees et al., 1988). In vitro studies have demonstrated that triiodothyronine (T3) stimulates chondrocytes hypertrophy together with molecular markers of differentiated chondrocytes (Burch and Lebovitz, 1982; Bohme et al., 1992; Wang et al., 2007). Mice lacking thyroid hormone receptor alpha-1 manifest typical features of skeletal hypothyroidism, postnatal growth retardation, and delayed endochondral ossification (O’Shea et al., 2005).

ANDROGENS

Androgens are important for male gonadal differentiation during fetal life, for sexual maturation and maintenance during and after puberty as well as genital function and spermatogenesis during adulthood. However, their impact on bone growth and development in men remains not fully understood.

The androgen receptor (AR) is widely expressed in growth plate cartilage of several species, including rat, rabbit, and human (Abu et al., 1997; Ben-Hur et al., 1997; Nilsson et al., 2003a). Unilateral injection of testosterone into the epiphyseal growth plate of the rat tibia expands the width of this growth plate in comparison to the contralateral one (Ren et al., 1989). Moreover, non-aromatizable androgens such as dihydrotosterone (DHT) and oxandrolone accelerate the rate of bone growth in patients without affecting systemic levels of GH (Stanhope et al., 1988; Veldhuis et al., 1997). In girls with Turner syndrome, oxandrolone has been used in combination with GH therapy and has been shown to increase both growth rate and adult height when given alone or in combination with GH (Batch, 2002). All mentioned evidences suggest that androgens have the capacity to stimulate bone growth, an effect which could be systemically and/or locally mediated. Oxandrolone...
has been found not to influence the growth of cultured fetal rat metatarsal bones suggesting that androgens in vivo might stimulate longitudinal bone growth by acting indirectly, rather than directly on growth plate chondrocytes (Chagin et al., 2009). Interestingly, Sun et al. (2011) recently reported that dehydroepiandrosterone (DHEA) suppresses the growth of cultured metatarsal bones by acting directly at the growth plate level through estrogen receptor (ER) interaction. This effect is however not surprising as DHEA is easily aromatized to estrogens, a process which may occur locally in the growth plate where the P450 aromatase (CYP19) is known to be expressed (Oz et al., 2001).

The evidence accumulated so far suggests that testosterone affects bone growth only after being, locally in the growth plate, aromatized to estrogens. Furthermore, despite demonstrating normal levels of testosterone both aromatase-deficient males and females exhibit the characteristic features of estrogen deficiency, i.e., an unfused epiphysis, markedly delayed bone development and severe osteopenia in adulthood (Morishima et al., 1995; Carani et al., 1997). Together, these findings indicate that estrogens should not be considered to be solely female hormones, but more generally as sex steroids required for normal bone growth and development in both females and males.

**ESTROGENS AND THE ESTROGEN RECEPTORS**

Estrogens influence target organs through two known nuclear receptors, estrogen receptor-α (ERα; Greene et al., 1986; Greene et al., 1986) and estrogen receptor-β (ERβ; Kuiper et al., 1996; Figure 2). These two receptors considered as classical ligand-activated transcription factors, located in the cytosol until binding their ligand. Then estrogen–ER complexes are translocated into the nucleus and interact with estrogen response elements (EREs) in the promoter regions of target genes. Additionally, estrogens bind to subpopulations of ERα and ERβ associated with the plasma membrane, thereby rapidly activating a variety of intracellular signaling cascades.

More recently, a membranous G-protein-coupled estrogen receptor (GPER; formerly named GPR30) that rapidly mediates estrogen signaling was discovered (Revankar et al., 2005). This receptor is widely expressed in the hypertrophic zone of human growth plate cartilage and the expression level decreases during pubertal progression, suggesting that GPER is involved in modulating longitudinal bone growth (Chagin and Sävendahl, 2007). Indeed, in vivo studies using genetically modified mice with targeted deletion of this receptor showed that GPER is required for normal estrogenic responses in the growth plate (Windahl et al., 2009).

**ENDOGENOUS PRODUCTION OF ESTROGEN**

Based on numerous in vivo and in vitro studies, it is now well established that chondrocytes can produce estrogens (Oz et al., 2001; Sylvia et al., 2002; van der Eerden et al., 2002). Expression of P450 aromatase in growth plate cartilage of both humans (Oz et al., 2001) and rats (van der Eerden et al., 2002; Chagin et al., 2006) further supports that chondrocytes have the potential to synthesize this hormone. Furthermore, local production of estrogens have been reported to be of importance for chondrocyte proliferation, protecting these cells from spontaneous cell death, and thereby regulating longitudinal bone growth (Chagin et al., 2006).

**ROLE OF ESTROGENS ON BONE MATURATION AND GROWTH PLATE FUSION**

Estrogens were first considered as female hormones primarily responsible for pubertal growth and sexual organ development in girls, acting similarly as androgens do in boys. This theory was challenged by Smith and his colleagues in the 1990s when they described a unique case of an extremely tall 28-year-old man who still had unfused epiphyses, a bone age of 15 years, and a lumbar spine BMD that was 3 SD below the appropriate control mean. He was 204 cm tall, had an arm span of 213 cm and eunuchoidal appearance structure, and, due to his open epiphyses, was still growing slowly during the third decade of his life. This patient did not respond to high doses of transdermal ethinyl estradiol (Smith et al., 1994). Laboratory tests revealed an inactivation mutation in the ERα gene, which led to a substitution of thymine for cytosine. He was described to have a normal serum androgen level supporting that the genetic estrogen resistance indeed was responsible for this skeletal disorder (Smith et al., 1994). Histomorphometrical analysis of his bones revealed markedly decreased mineral content and impaired bone structure although the periosteal circumference was unaffected (Smith et al., 2008).

A year later, in 1995, a similar phenotype appearance was described by Morishima and his colleagues. DNA tests revealed a homozygous mutation of the aromatase P450 (CYP19) gene that led to high levels of androgens and undetectable levels of estradiol in the serum (Morishima et al., 1995; Zirilli et al., 2009).
In contrast to the ERα-mutated man, this patient responded to high-dose estrogens.

These case reports indicate that androgen alone is not enough to advance skeletal maturation and maintain bone mass. Moreover, they demonstrate that estrogens play an important role in bone mineralization in both sexes. The expression of ERs in growth plate chondrocytes of different species (Nilsson et al., 1999, 2002) suggests that estrogens directly affect growth plate chondrocytes.

**ESTROGEN TREATMENT FOR MODULATION OF BONE GROWTH**

High-dose estrogen therapy has been documented to effectively reduce adult height in extremely tall girls (Goldzieher, 1956; Venn et al., 2008). However, the long-term effects of such treatment has to be considered. It has been reported that high-dose estrogen therapy may reduce fertility later in life (Venn et al., 2004; Hendriks et al., 2011) and even induce premature ovarian failure (Hendriks et al., 2011), increase the risk for deep vein thrombosis (Weimann and Brack, 1996), as well as, possibly, increase the risk for breast and gynecological cancers (Genazzani et al., 2001). Conversely, inhibition of estrogen biosynthesis by administering an aromatase inhibitor in patients with idiopathic short stature successfully delays skeletal maturation and enhances adult height (Hero et al., 2005). Later, it was reported that such treatment with an aromatase inhibitor may increase bone resorption (Hero et al., 2003). Furthermore, 2 years treatment of pre- or early-pubertal idiopathic short stature males with an aromatase inhibitor led to vertebral deformities (Hero et al., 2010), again emphasizing the importance of estrogens for bone health, not only in females but also in males.

**SELECTIVE ESTROGEN RECEPTOR MODULATORS**

Unlike estrogens, which are all agonists, and antiestrogens, which are all antagonists, selective estrogen receptor modulators (SERMs) include a diversity of compounds that can act as either ER agonists or antagonists in a tissue-specific manner (Cho and Nuttall, 2001). They dissociate desirable estrogen effects on bone from undesirable stimulatory effects on the breast and endometrium. Despite lacking the steroid structure of estrogens, their tertiary structure allows them to bind to the ERs. Most, of these distinct activities on target tissues for estrogens can be explained by three major interacting factors: differences in expression levels of ERα and ERβ, differences in the conformational changes upon binding of ligand to ERs, and differences in the expression of coregulator proteins (coactivators or corepressors; Riggs and Hartmann, 2003).

Tamoxifen, a first generation SERM, has been used to treat pubertal gynecomastia in adolescent boys (Derman et al., 2003; Lawrence et al., 2004) and precocious puberty in patients with McCune–Albright Syndrome (Eugster et al., 2003). In these studies, longitudinal growth was either unaffected or diminished following months of treatment (Derman et al., 2003; Eugster et al., 2003; Lawrence et al., 2004). In an ex vivo model of cultured fetal rat metatarsal bones we earlier reported that tamoxifen may induce permanent growth arrest (Chagin et al., 2007). Indeed, in vivo data in male rats verified that tamoxifen impairs longitudinal bone growth, an effect which is accompanied by cortical bone growth destruction (Karimian et al., 2008).

Raloxifene, another SERM, acts as an estrogen agonist in bone and as an estrogen antagonist in breast and uterine tissues (Barrett-Connon, 2001). In rats, this compound inhibits longitudinal bone growth (Evans et al., 1994) while in ovariectomized rabbits it acts as an estrogen agonist on the growth plate accelerating chondrocyte senescence and thereby hastening epiphyseal fusion (Nilsson et al., 2003b). In contrast, Zirilli et al. (2009) recently reported that, unlike in rats and rabbits, raloxifene do not accelerate epiphyseal fusion, but does enhance BMD and circulating levels of gonadotropins in aromatase-deficient humans.

**CONCLUSION**

A better understanding of the genetic regulation of growth plate cartilage could open for novel therapeutic strategies in children with different growth disorders. As illustrated in this review, it is difficult to extrapolate data obtained in experimental animals to the human growth plate. This emphasizes the urgent need for new experimental models that will allow studies in human growth plate cartilage.

**REFERENCES**

Abu, E. O., Hornner, A., Kusec, V., Triffitt, J. T., and Compston, J. E. (1997). The localization of androgen receptors in human bone. *J. Clin. Endocrinol. Metab.* 82, 3493–3497.

Abu, E. O., Hornner, A., Kusec, V., Triffitt, J. T., and Compston, J. E. (2000). The localization of the functional glucocorticoid receptor alpha in human bone. *J. Clin. Endocrinol. Metab.* 85, 883–889.

Ahrens, M. J., Li, Y., Jiang, H., and Dudley, A. T. (2009). Convergent extension movements in growth plate chondrocytes require gpi-anchored cell surface proteins. *Development* 136, 3463–3474.

Allen, D. B. (1996). Growth suppression by glucocorticoid therapy. *Endocrinol. Metab. Clin. North Am.* 25, 699–717.

Altman, A., Hochberg, Z., and Silbermann, M. (1992). Interactions between growth hormone and dexamethasone in skeletal growth and bone structure of the young mouse. *Calcif. Tissue Int.* 51, 298–304.

Ballock, R. T., and O’Keefe, R. J. (2004). The biology of the growth plate. *J. Bone Joint Surg.* Am. 85-A, 715–726.

Baron, J., Huang, Z., Oerter, K. E., Bacher, J. D., and Caillet, G. B. Jr. (1992). Dexamethasone acts locally to inhibit longitudinal bone growth in rabbits. *Am. J. Physiol.* 263, E489–E492.

Bauert-Connon, E. (2001). Raloxifene: risks and benefits. *Ann. N. Y. Acad. Sci.* 949, 295–303.

Bastpe, M., Weinstein, L. S., Ogata, N., Kawaguchi, H., Juppner, H., Kronenberg, H. M., and Chung, U. I. (2004). Stimulatory G protein directly regulates hypertrophic differentiation of growth plate cartilage in vivo. *Proc. Natl. Acad. Sci. U.S.A.* 101, 14794–14799.

Batch, J. (2002). Turner syndrome in childhood and adolescence. *Best Pract. Res. Clin. Endocrinol. Metab.* 16, 465–482.

Baur, S. T., Mai, J. J., and Dymecki, S. M. (2000). Combinatorial signaling through BMP receptor IB and GDF5: shaping of the distal mouse limb and the genetics of distal limb diversity. *Development* 127, 605–619.

Ben-Hur, H., Thole, H. H., Mashiah, A., Insler, V., Berman, V., Shezen, E., Elias, D., Zuckerman, A., and Ornoy, A. (1997). Estrogen, progesterone and testosterone receptors in human fetal cartilaginous tissue: immunohistochemical studies. *Calcif. Tissue Int.* 60, 520–526.

Bohme, K., Consience-Egli, M., Tschau, T., Winterhalter, K. H., and Bruckner, P. (1992). Induction of proliferation or hypertrophy of chondrocytes in serum-free culture: the role of insulin-like growth factor-I, insulin, or thyroid hormone. *J. Cell Biol.* 116, 1035–1042.

Boisclair, Y. R., Rhoads, R. P., Ueki, L., Wang, J., and Oei, G. T. (2001). The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. *J. Endocrinol.* 170, 63–70.

Karimian et al. Genetic regulation of the growth plate
Burch, W. M., and Lebovitz, H. E. (2002). Differential regulation of growth plate chondrocytes by 1alpha,25(OH)2D3 and 24R,25(OH)2D3 involves cell-maturation-specific membrane-receptor-activated phospholipid metabolism. Crit. Rev. Oral Biol. Med. 13, 143–154.

Boyan, B. D., Sylvia, V. L., Dean, D. D., Del Toro, F., and Schwartz, Z. (2002). Genetic regulation of the growth plate involves cell-maturation-specific membrane-receptor-activated phospholipid metabolism. Crit. Rev. Oral Biol. Med. 13, 143–154.

Karimian et al. Genetic regulation of the growth plate

Boyce, W. J., and Swaab, D. F. (1991). Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Horm. Res. 37, 290–297.

Karimian et al. Genetic regulation of the growth plate

Boyce, W. J., and Swaab, D. F. (1991). Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Horm. Res. 37, 290–297.

Hendriks, A. E., Laven, J. S., Valkenburg, O., Fong, S. L., Fauser, B. C., De Ridder, M. A., De Jong, F. H., Visser, I. A., Van Ginneken, A. M., Boot, A. M., and Drop, S. L. (2011). Fertility and ovarian function in high-dose estrogen-treated tall women. J. Clin. Endocrinol. Metab. 96, 1098–1105.

Hero, M., Makite, O., Kroger, H., Nousiainen, E., Toivainen-Salo, S., and Dunkel, L. (2009). Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Horm. Res. 71, 290–297.

Hirata, M., Kugimiya, F., Fukai, A., Ohba, S., Kawamura, N., Ogawara, T., Kakizaki, Y., Saito, T., Yano, F., Ikeda, T., Nakamura, K., Chung, U. I., and Kawaguchi, H. (2003). CEBP beta Promotes transi- tion from proliferation to hyper- tropic differentiation of chon- drocytes through transactivation of p57. PLoS ONE 4, e4543. doi:10.1371/journal.pone.0004543

Henneberg, W. J., and Swaab, D. F. (1973). The influence of anencephaly upon intrauterine growth of fetus and placenta and upon gestation length. J. Obstet. Gynaecol. Br. Commonwealth 80, 577–588.

Horton, W. A., Hall, J. G., and Hecht, J. T. (2007). Achenchondroplasia. Lancet 370, 162–172.

Isaksson, O. G., Lindahl, A., Nilsson, A., and Isgaard, J. (1987). Mechanism of the stimulatory effect of growth hor- mone on longitudinal bone growth. Endocr. Rev. 8, 426–438.

Iwamoto, T., Nakamura, T., Doyle, A., Ishikawa, M., De Vega, S., Fukumoto, S., and Yamada, Y. (2010). Pannexin

www.frontiersin.org
Poznanski, A. K., Werder, E. A., Giedion, A., Martin, A., and Shaw, H. (1977). The pattern of shortening of the bones of the hand in PHP and PPHP – a comparison with brachydactyly E, Turner Syndrome, and acrodysostosis. Radiology 123, 707–718.

Ren, S. G., Malozowski, S., Sanchez, P., Sweet, D. E., Loriaux, D. L., and Cassorla, F. (1989). Direct administration of testosterone increases rat tibial epiphyseal growth plate width. Acta Endocrinol. 121, 401–405.

Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., and Pronsitz, E. R. (2005). A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307, 1623–1626.

Riggs, B. L., and Hartmann, L. C. (2003). Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N. Engl. J. Med. 348, 618–629.

Rivkees, S. A., Bode, H. H., and Crawford, J. D. (1988). Long-term growth in juvenile acquired hypothyroidism: the failure to achieve normal adult stature. N. Engl. J. Med. 318, 599–602.

Rosenzweig, A., and Seidman, C. E. (1991). Atrial natriuretic factor and related peptide hormones. Annu. Rev. Biochem. 60, 229–255.

Schipani, E., Langman, C. B., Parfitt, R. C., Rosenzweig, A., and Seidman, C. E. (2004). Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J. Clin. Endocrinol. Metab. 93, 3088–3096.

Stanhope, R., Buchanan, C. R., Fenn, G. C., and Preece, M. A. (1998). Double blind placebo controlled trial of low dose oxandrolone in the treatment of boys with constitutional delay of growth and puberty. Arch. Dis. Child. 63, 501–505.

Steinbach, H. L., and Young, D. A. (1966). The roentgen appearance of pseudohypoparathyroidism (PH) and pseudo-pseudohypoparathyroidism (PPPH). Differentiation from other syndromes associated with short metacarpals, metatarsals, and phalanges. Am. J. Roentgenol. Radium Ther. Neur. Med. 97, 49–66.

Steinert, A. E., Proffen, B., Kunz, M., Hendrich, C., Ghivizzani, S. C., Noth, U., Rethwilm, A., Euler, J., and Evans, C. H. (2009). Hypertrophy is induced during the in vitro chondrogenic differentiation of human mesenchymal stem cells by bone morphogenetic protein-2 and bone morphogenetic protein-4 gene transfer. Arthritis Res. Ther. 11, R148.

St-Jacques, B., Hammerschmidt, M., and McMahon, A. P. (1999). Inducible hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13, 2072–2086.

Storm, E. E., and Kingsley, D. M. (1999). GDF5 coordinates bone and joint formation during digit development. Dev. Biol. 219, 11–27.

Stratigosopoulos, E., Szabolcs, M., Dragatis, S., Klinakis, A., and Efstathiadis, A. (2008). The hormonal action of IGF1 in postnatal mouse growth.

Venn, A., Hosmer, T., Hosmer, D., Bruinisma, F., Jones, P., Lumley, J., Pyett, P., Rayner, J. A., and Werther, G. (2008). Oestrogen treatment for tall stature in girls: estimating the effect on height and the error in height prediction. Clin. Endocrinol. (Oxf.) 68, 926–929.

Wang, L., Shao, Y. Y., and Ballock, R. T. (2007). Thyroid hormone interacts with the Wnt/beta-catenin signaling pathway in the terminal differentiation of growth plate chondrocytes. J. Bone Miner. Res. 22, 1988–1995.

Waters, M. J., and Kaye, P. L. (2002). The role of growth hormone in fetal development. Growth Horm. IGF Res. 12, 137–146.

Weimann, E., and Brack, C. (1996). Severe thrombosis during treatment with estradiol. J. Pediatr. for tall stature. Horm. Res. 45, 261–263.

Wendahl, S. H., Andersson, N., Chagin, A. S., Martensson, U. E., Carlsten, H., Olde, B., Swanson, C., Moverare-Skritic, S., Savendlah, L., Lagerquist, M. K., Leeb-Lundberg, L. M., and Ohlsson, C. (2009). The role of the G protein-coupled receptor GPR30 in the effects of estrogen in ovarioectomized mice. Am. J. Physiol. Endocrinol. Metab. 296, E490–E496.

Woods, A., Khan, S., and Beier, F. (2007). C-type natriuretic peptide regulates cellular condensation and glycosaminoglycan synthesis during chondrogenesis. Endocrinology 148, 5030–5041.

Wood, K. A., Camacho-Hubner, C., Savage, M. O., and Clark, A. J. (1996). Intragenital growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N. Engl. J. Med. 335, 1363–1367.

Xue, Y., and Fleet, J. C. (2009). Intestinal vitamin D receptor is required for normal calcium and bone metabolism in mice. Gastroenterology 136, 1317–1327, e1311–e1312.

Yakar, S., Rosen, C. J., Bouxsein, M. L., Sun, H., Meija, W., Kawashima, Y., Wu, Y., Emerton, K., Williams, V., Jepsen, K., Schaffer, M. B., Majeska, R. J., Gavriloa, O., Gutierrez, M., Hwang, D., Pennisi, P., Fryskyt, J., Boisclair, Y., Pintar, J., Jasper, H., Domene, H., Cohen, P., Clemmons, D., and Leroith, D. (2009). Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. PASEJ 23, 709–719.

Yang, T., Mendoza-Londono, R., Lu, H., Tio, J., Li, K., Keller, B., Jiang, M. M., Shah, R., Chen, Y., Bertin, T. K., Engin, F., Dabovic, B., Rikf, D. B., Hicks, J., Iamrich, M., Beaudet, A. L.,
Zhang, F., Qiu, T., Wu, X., Wan, C., Shi, W., Wang, Y., Chen, J. G., Wan, M., Clemens, T. L., and Cao, X. (2009). Sustained BMP signaling in osteoblasts stimulates bone formation by promoting angiogenesis and osteoblast differentiation. J. Bone Miner. Res. 24, 1224–1233.

Zhang, P., Jobert, A. S., Couvineau, A., and Silve, C. (1998). A homozygous inactivating mutation in the parathyroid hormone/parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia. J. Clin. Endocrinol. Metab. 83, 3365–3368.

Zhang, X., Ibrahimi, O. A., Olsen, S. K., Umemori, H., Mohammadi, M., and Ornitz, D. M. (2006). Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 281, 15694–15700.

Zirilli, L., Maffei, L., Meunier, P. I., Chavassieux, P., Carani, C., and Rochira, V. (2009). The effects of long-term raloxifene and estradiol treatments on bone in a patient with congenital aromatase deficiency. Bone 45, 827–832.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.